Biotechnology firm prepares to bring its LX6 pathogen detection system online and the machine towards commercialisation this year
LexaGene Holdings Inc., a US-based biotechnology company that develops instrumentation for pathogen detection, has announced the expansion of its operations in Massachusetts. The firm recently signed a lease for a 17,500-square-foot space, located at 500 Cummings Center, Suite 4550, in Beverly.
"As LexaGene started ramping up our operations in December to meet our 2018 goals, we have leased a larger space to grow into which will support our R&D and manufacturing efforts moving forward," said Dr Jack Regan, LexaGene's CEO.
LexaGene is installing a state-of-the-art, level-two biosafety laboratory. The new facility will allow LexaGene to adhere to biocontainment precautions, specified by the CDC, while testing for dangerous pathogens, such as E. coli and Staphylococcus.
Additionally, over the last several weeks LexaGene made six key new hires, and the company plans to bring an additional 20 new employees on board in the coming weeks in anticipation of this growth. “The Beverly location is also particularly ideal for us since it allows us to tap into the very talented pool of engineers and scientists in the Boston area,” Regan added.
Dr Regan also pointed out that 2018 is going to be a significant year for the company as it prepares to bring the LX6 pathogen detection system online and move the machine towards commercialisation.
LexaGene is a biotechnology company developing what is deemed to be the very first fully automated pathogen detection platform that is open-access, the LX6.
The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customised pathogen detection.
The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.